Investors jazzed after hours over positive test results for fibromyalgia treatment(2)
Shares of Palo Alto’s Jazz Pharmaceuticals rose by more than a third in after hours trading Wednesday after the company reported positive results from the second of its Phase III clinical trials of sodium oxybate, a treatment for the chronic illness known as fibromyalgia known for the widespread pain and chronic fatigue it induces. The drug is being developed jointly with Read the rest of this entry »
Subscribe via RSS all feeds